Clinical trials: Age
Hypertension
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
- Trial name
- NCT01420068
- Testing
- SPP100
- Where
- 25 sites in United States, Guatemala and 5 more
- Volunteers
- 106 people
- Sponsor
- LXO Group
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hereditary Angioedema, Pediatric
Berotralstat Treatment in Children With Hereditary Angioedema
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years of age for prophylactic…
- Trial name
- APeX-P (NCT05453968)
- Testing
- Berotralstat
- Where
- 15 sites in Austria, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- BioCryst Pharmaceuticals
Transfusion, Age of Blood
Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage.
- Trial name
- TRANSFUSE (NCT01638416)
- Testing
- Blood transfusion
- Where
- 60 sites in Australia, Finland and 3 more
- Volunteers
- 4,994 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and…
- Trial name
- NCT02214225
- Testing
- Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
- Where
- 33 sites in United States
- Volunteers
- 3,484 people, healthy volunteers welcome
- Sponsor
- Seqirus
Dry Age-related Macular Degeneration
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- EXPLORE (NCT04437368)
- Testing
- GT005
- Where
- 55 sites in United States, Australia and 6 more
- Volunteers
- 98 people
- Sponsor
- Gyroscope Therapeutics Limited
Perennial Allergic Rhinitis
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
- Trial name
- GSP 301-303 (NCT02709538)
- Testing
- GSP 301 NS
- Where
- 34 sites in United States
- Volunteers
- 601 people
- Sponsor
- Glenmark Specialty S.A.
Peanut Allergy
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
- Trial name
- EPITOPE (NCT03211247)
- Testing
- Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part B Viaskin Peanut 250 mcg
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- DBV Technologies
Healthy
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.
- Trial name
- NCT00092417
- Testing
- Comparator: Varicella Zoster Virus Vaccine
- Volunteers
- 695 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00550550
- Testing
- SCH 697243, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment
- Volunteers
- 345 people
- Sponsor
- ALK-Abelló A/S
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Diffuse Large B-Cell Lymphoma
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma.
- Trial name
- NCT02420210
- Testing
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Pneumococcal Disease
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
- Trial name
- NCT04642079
- Testing
- 20vPnC
- Where
- 43 sites in United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Bronchiolitis
Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
This is a multi-center, parallel, double-blind, randomized controlled clinical trial. Children <12 months of age hospitalized with bronchiolitis are randomized 1:1 to receive a 24-week home intervention with filtration units…
- Trial name
- BREATHE (NCT05615870)
- Testing
- Winix 5500-2 HEPA filtration units
- Where
- 17 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Respiratory Syncytial Virus Prevention
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
The purpose of this study is to demonstrate non-inferiority in terms of humoral immune responses of Ad26.RSV.preF-based study vaccine lots representative of different aged vaccine in comparison to a non-aged Ad26.RSV.preF-based…
- Trial name
- NCT05101486
- Testing
- Ad26.RSV.PreF-based Vaccine
- Where
- 13 sites in United States
- Volunteers
- 755 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT02466386
- Testing
- SPD489
- Where
- 50 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
Neisseria Meningitidis, Haemophilus Influenzae Type b
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) vaccine co-administered with Rotarix, Prevnar 13 and Havrix as compared to PedvaxHIB…
- Trial name
- NCT01978093
- Testing
- Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®
- Where
- 26 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to compare the effect of 6 weeks of treatment with beclomethasone dipropionate (BDP) nasal aerosol versus placebo on HPA-axis function, as assessed by 24-hour serum cortisol weighted mean, and to…
- Trial name
- NCT01697956
- Testing
- BDP
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.